Literature DB >> 8523556

Inter- and intraclade neutralization of human immunodeficiency virus type 1: genetic clades do not correspond to neutralization serotypes but partially correspond to gp120 antigenic serotypes.

J P Moore1, Y Cao, J Leu, L Qin, B Korber, D D Ho.   

Abstract

We have studied genetic variation among clades A through E of human immunodeficiency virus type 1 (HIV-1) at the levels of antibody binding to gp120 molecules and virus neutralization. We are unable to identify neutralization serotypes that correspond to the genetic clades. Instead, we observe that inter- and intraclade neutralization of primary isolates by HIV-1-positive sera is generally weak and sporadic; some sera show a reasonable degree of neutralization breadth and potency whereas others are relatively sensitive to neutralization, but no consistent pattern was found. However, a few sera were able to neutralize across clades with significant potency, an observation which may have implications for the feasibility of a broadly effective HIV-1 vaccine involving humoral immunity. Serological assays measuring anti-gp120 antibody binding also failed to identify serotypes that correspond precisely to the genetic clades, but some indications of clade-specific binding were observed, notably with sera from clades B and E. A representative protein for each clade (A through E) was selected on the basis of its specificity, defined as high seroreactivity with sera from individuals infected with virus of that clade and lower reactivity with sera from individuals infected with viruses from other clades. The seroreactivity patterns against these five proteins could be used to predict the genotype of the infecting virus with moderate success.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8523556      PMCID: PMC189832     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  53 in total

1.  Measuring vaccine-induced HIV neutralization: report of a workshop.

Authors:  C V Hanson
Journal:  AIDS Res Hum Retroviruses       Date:  1994-06       Impact factor: 2.205

2.  Dilemma of neutralization resistance of HIV-1 field isolates and vaccine development.

Authors:  T J Matthews
Journal:  AIDS Res Hum Retroviruses       Date:  1994-06       Impact factor: 2.205

3.  Biological, serological, and genetic characterization of HIV-1 subtype E isolates from northern Thailand.

Authors:  H Ichimura; S C Kliks; S Visrutaratna; C Y Ou; M L Kalish; J A Levy
Journal:  AIDS Res Hum Retroviruses       Date:  1994-03       Impact factor: 2.205

4.  Development of the anti-gp120 antibody response during seroconversion to human immunodeficiency virus type 1.

Authors:  J P Moore; Y Cao; D D Ho; R A Koup
Journal:  J Virol       Date:  1994-08       Impact factor: 5.103

5.  Genomic cloning and complete sequence analysis of a highly divergent African human immunodeficiency virus isolate.

Authors:  M Vanden Haesevelde; J L Decourt; R J De Leys; B Vanderborght; G van der Groen; H van Heuverswijn; E Saman
Journal:  J Virol       Date:  1994-03       Impact factor: 5.103

6.  A new subtype of human immunodeficiency virus type 1 (MVP-5180) from Cameroon.

Authors:  L G Gürtler; P H Hauser; J Eberle; A von Brunn; S Knapp; L Zekeng; J M Tsague; L Kaptue
Journal:  J Virol       Date:  1994-03       Impact factor: 5.103

7.  Neutralizing antibody responses to autologous and heterologous isolates of human immunodeficiency virus.

Authors:  T Wrin; L Crawford; L Sawyer; P Weber; H W Sheppard; C V Hanson
Journal:  J Acquir Immune Defic Syndr (1988)       Date:  1994-03

8.  Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome.

Authors:  R A Koup; J T Safrit; Y Cao; C A Andrews; G McLeod; W Borkowsky; C Farthing; D D Ho
Journal:  J Virol       Date:  1994-07       Impact factor: 5.103

9.  Two antigenically distinct subtypes of human immunodeficiency virus type 1: viral genotype predicts neutralization serotype.

Authors:  J R Mascola; J Louwagie; F E McCutchan; C L Fischer; P A Hegerich; K F Wagner; A K Fowler; J G McNeil; D S Burke
Journal:  J Infect Dis       Date:  1994-01       Impact factor: 5.226

10.  Genetic analysis of human immunodeficiency virus type 1 strains from patients in Cyprus: identification of a new subtype designated subtype I.

Authors:  L G Kostrikis; E Bagdades; Y Cao; L Zhang; D Dimitriou; D D Ho
Journal:  J Virol       Date:  1995-10       Impact factor: 5.103

View more
  80 in total

1.  Minimal incidence of serum antibodies reactive with intact primary isolate virions in human immunodeficiency virus type 1-infected individuals.

Authors:  L A Cavacini; J E Peterson; E Nappi; M Duval; R Goldstein; K Mayer; M R Posner
Journal:  J Virol       Date:  1999-11       Impact factor: 5.103

2.  Immunotyping of human immunodeficiency virus type 1 (HIV): an approach to immunologic classification of HIV.

Authors:  S Zolla-Pazner; M K Gorny; P N Nyambi; T C VanCott; A Nádas
Journal:  J Virol       Date:  1999-05       Impact factor: 5.103

Review 3.  Genetic subtypes, humoral immunity, and human immunodeficiency virus type 1 vaccine development.

Authors:  J P Moore; P W Parren; D R Burton
Journal:  J Virol       Date:  2001-07       Impact factor: 5.103

4.  A human immunodeficiency virus prime-boost immunization regimen in humans induces antibodies that show interclade cross-reactivity and neutralize several X4-, R5-, and dualtropic clade B and C primary isolates.

Authors:  F Verrier; S Burda; R Belshe; A M Duliege; J L Excler; M Klein; S Zolla-Pazner
Journal:  J Virol       Date:  2000-11       Impact factor: 5.103

5.  HIV neutralizing antibodies: clinical correlates and implications for vaccines.

Authors:  Nicole A Doria-Rose
Journal:  J Infect Dis       Date:  2010-04-01       Impact factor: 5.226

6.  Genetic and neutralization properties of subtype C human immunodeficiency virus type 1 molecular env clones from acute and early heterosexually acquired infections in Southern Africa.

Authors:  Ming Li; Jesus F Salazar-Gonzalez; Cynthia A Derdeyn; Lynn Morris; Carolyn Williamson; James E Robinson; Julie M Decker; Yingying Li; Maria G Salazar; Victoria R Polonis; Koleka Mlisana; Salim Abdool Karim; Kunxue Hong; Kelli M Greene; Miroslawa Bilska; Jintao Zhou; Susan Allen; Elwyn Chomba; Joseph Mulenga; Cheswa Vwalika; Feng Gao; Ming Zhang; Bette T M Korber; Eric Hunter; Beatrice H Hahn; David C Montefiori
Journal:  J Virol       Date:  2006-09-13       Impact factor: 5.103

7.  Cross-clade human immunodeficiency virus (HIV)-specific cytotoxic T-lymphocyte responses in HIV-infected Zambians.

Authors:  M R Betts; J Krowka; C Santamaria; K Balsamo; F Gao; G Mulundu; C Luo; N N'Gandu; H Sheppard; B H Hahn; S Allen; J A Frelinger
Journal:  J Virol       Date:  1997-11       Impact factor: 5.103

8.  Broadly neutralizing antibodies targeted to the membrane-proximal external region of human immunodeficiency virus type 1 glycoprotein gp41.

Authors:  M B Zwick; A F Labrijn; M Wang; C Spenlehauer; E O Saphire; J M Binley; J P Moore; G Stiegler; H Katinger; D R Burton; P W Parren
Journal:  J Virol       Date:  2001-11       Impact factor: 5.103

9.  A comprehensive panel of near-full-length clones and reference sequences for non-subtype B isolates of human immunodeficiency virus type 1.

Authors:  F Gao; D L Robertson; C D Carruthers; S G Morrison; B Jian; Y Chen; F Barré-Sinoussi; M Girard; A Srinivasan; A G Abimiku; G M Shaw; P M Sharp; B H Hahn
Journal:  J Virol       Date:  1998-07       Impact factor: 5.103

Review 10.  Inhibition of HIV Entry by Targeting the Envelope Transmembrane Subunit gp41.

Authors:  Hyun A Yi; Brian C Fochtman; Robert C Rizzo; Amy Jacobs
Journal:  Curr HIV Res       Date:  2016       Impact factor: 1.581

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.